ReviewCNS drugs2015
Fertility, pregnancy and childbirth in patients with multiple sclerosis: impact of disease-modifying drugs.
Review in CNS drugs, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis.The Cochrane database of systematic reviews · 2023Pooled it
- Potential Protective Role of Pregnancy and Breastfeeding in Delaying Onset Symptoms Related to Multiple Sclerosis.Medicina (Kaunas, Lithuania) · 2023Pooled it
- Assisted Reproduction Therapy in Patients with Multiple Sclerosis: Narrative Review and Practical Recommendations.Healthcare (Basel, Switzerland) · 2025Review
- Pregnancy and Infant Outcomes in Multiple Sclerosis: Findings From the Global MAPLE-MS Pharmacovigilance Program.Neurology(R) neuroimmunology & neuroinflammation · 2025Article
- Multiple sclerosis, urinary tract infections and infertility: a comprehensive scoping review.Journal of the Turkish German Gynecological Association · 2025Article
- Topical review: Lactation and use of DMTs in women with MS.Multiple sclerosis (Houndmills, Basingstoke, England) · 2024Review
- Pregnancy effect on disease activity in women with multiple sclerosis treated with cladribine.Journal of neurology · 2024Article
- Multiple Sclerosis and Family Planning: A Survey Study of the Patient Experience.Neurology. Clinical practice · 2024Article
- Assisted Reproductive Techniques in Multiple Sclerosis: Recommendations from an Expert Panel.Neurology and therapy · 2023Review
- Optimizing the "Time to pregnancy" in women with multiple sclerosis: the OPTIMUS Delphi survey.Frontiers in neurology · 2023Article
- Updated Perspectives on the Challenges of Managing Multiple Sclerosis During Pregnancy.Degenerative neurological and neuromuscular disease · 2022Review
- A systematic review of relapse rates during pregnancy and postpartum in patients with relapsing multiple sclerosis.Therapeutic advances in neurological disorders · 2021Review
- Family Planning Decision Making in People With Multiple Sclerosis.Frontiers in neurology · 2021Article
- Is Fertility Affected in Women of Childbearing Age with Multiple Sclerosis or Neuromyelitis Optica Spectrum Disorder?Journal of molecular neuroscience : MN · 2020Article
- Teriflunomide-exposed pregnancies in a French cohort of patients with multiple sclerosis.Neurology. Clinical practice · 2020Article
- Twin pregnancy outcome following teriflunomide treatment in a relapsing-remitting multiple sclerosis patient: A case report.Medicine · 2020Article
- Pregnancy and the Postpartum Period in Women With Relapsing-Remitting Multiple Sclerosis Treated With Old and New Disease-Modifying Treatments: A Real-World Multicenter Experience.Frontiers in neurology · 2020Article
- Protection of Male Rat Offspring against Hypertension Programmed by Prenatal Dexamethasone Administration and Postnatal High-Fat Diet with the Nrf2 Activator Dimethyl Fumarate during Pregnancy.International journal of molecular sciences · 2019Article
- Women's Health: Contemporary Management of MS in Pregnancy and Post-Partum.Biomedicines · 2019Review
- Factors interfering with parenthood decision-making in an Italian sample of people with multiple sclerosis: an exploratory online survey.Journal of neurology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent decades, pregnancy-related issues in multiple sclerosis (MS) have received growing interest. MS is more frequent in women than in men and typically starts during child-bearing age. An increasing number of disease-modifying drugs (DMDs) for the treatment of MS are becoming available. Gathering information on their influences on pregnancy-related issues is of crucial importance for the counselling of MS patients. As for the immunomodulatory drugs (interferons and glatiramer acetate), accumulating evidence points to the relative safety of pregnancy exposure in terms of maternal and foetal outcomes. In case of higher clinical disease activity before pregnancy, these drugs could be continued until conception. As for the 'newer' drugs (fingolimod, natalizumab, teriflunomide, dimethyl fumarate and alemtuzumab), the information is more limited. Whereas fingolimod and teriflunomide are likely associated with an increased risk of foetal malformations, the effects of natalizumab, dimethyl fumarate and alemtuzumab still need to be ascertained. This article provides a review of the available information on the use of DMDs during pregnancy, with a specific focus on fertility, foetal development, delivery and breast-feeding.
Indexed as
Identifiers
25773609What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.